Patient Profile 2: R/R Follicular Lymphoma with Early Disease Progression

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Prior bendamustine exposure correlated with worse complete response rates with axi-cel among those with relapsed/refractory follicular lymphoma.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Data showed no significant differences in the incidence of CRS and ICANS with the use prophylactic dexamethasone in a retrospective review.

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.